|Other Names||Interleukin-17D, IL-17D, Interleukin-27, IL-27, IL17D, IL27|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1707a was selected from the N-term region of human L27 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells.|
|Tissue Location||Expressed preferentially in adipose, skeletal muscle and CNS.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
L27 is a cytokine that shares the sequence similarity with IL17. The treatment of endothelial cells with this cytokine has been shown to stimulate the production of other cytokines including IL6, IL8 and CSF2/ GM-CSF. The increased expression of IL8 induced by this cytokine was found to be NF-kappa B-dependent.
Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003).Starnes, T., et al., J. Immunol. 169(2):642-646 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.